314 related articles for article (PubMed ID: 34148613)
1. Immunotherapy in colorectal cancer.
Agarwal P; Le DT; Boland PM
Adv Cancer Res; 2021; 151():137-196. PubMed ID: 34148613
[TBL] [Abstract][Full Text] [Related]
2. Targeting MSS colorectal cancer with immunotherapy: are we turning the corner?
Wang C; Fakih M
Expert Opin Biol Ther; 2021 Oct; 21(10):1347-1357. PubMed ID: 34030532
[TBL] [Abstract][Full Text] [Related]
3. The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer.
Chen Y; Zheng X; Wu C
Front Immunol; 2021; 12():792691. PubMed ID: 34925375
[TBL] [Abstract][Full Text] [Related]
4. T Cells in Colorectal Cancer: Unravelling the Function of Different T Cell Subsets in the Tumor Microenvironment.
Zheng Z; Wieder T; Mauerer B; Schäfer L; Kesselring R; Braumüller H
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511431
[TBL] [Abstract][Full Text] [Related]
5. Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy.
Bai Z; Zhou Y; Ye Z; Xiong J; Lan H; Wang F
Front Immunol; 2021; 12():808964. PubMed ID: 35095898
[TBL] [Abstract][Full Text] [Related]
6. Microsatellite Instability and Immune Response: From Microenvironment Features to Therapeutic Actionability-Lessons from Colorectal Cancer.
Greco L; Rubbino F; Dal Buono A; Laghi L
Genes (Basel); 2023 May; 14(6):. PubMed ID: 37372349
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy of microsatellite stable colorectal cancer: resistance mechanisms and treatment strategies.
Han YJ; Shao CY; Yao Y; Zhang Z; Fang MZ; Gong T; Zhang YJ; Li M
Postgrad Med J; 2024 May; 100(1184):373-381. PubMed ID: 38211949
[TBL] [Abstract][Full Text] [Related]
8. Towards exertion of immunotherapeutics in the treatment of colorectal cancer; adverse sides, challenges, and future directions.
Pan W; Zhao J; Zhang S; Chen X; Liang W; Li Q
Int Immunopharmacol; 2021 Dec; 101(Pt B):108337. PubMed ID: 34775366
[TBL] [Abstract][Full Text] [Related]
9. How to overcome tumor resistance to anti-PD-1/PD-L1 therapy by immunotherapy modifying the tumor microenvironment in MSS CRC.
Chen L; Jiang X; Li Y; Zhang Q; Li Q; Zhang X; Zhang M; Yu Q; Gao D
Clin Immunol; 2022 Apr; 237():108962. PubMed ID: 35227870
[TBL] [Abstract][Full Text] [Related]
10. Cell-based immunotherapy approaches for colorectal cancer: main achievements and challenges.
Shahnazari M; Samadi P; Pourjafar M; Jalali A
Future Oncol; 2021 Aug; 17(24):3253-3270. PubMed ID: 34156258
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in colorectal cancer: rationale, challenges and potential.
Ganesh K; Stadler ZK; Cercek A; Mendelsohn RB; Shia J; Segal NH; Diaz LA
Nat Rev Gastroenterol Hepatol; 2019 Jun; 16(6):361-375. PubMed ID: 30886395
[TBL] [Abstract][Full Text] [Related]
12. A new strategy for immunotherapy of microsatellite-stable (MSS)-type advanced colorectal cancer: Multi-pathway combination therapy with PD-1/PD-L1 inhibitors.
Cai L; Chen A; Tang D
Immunology; 2024 Mar; ():. PubMed ID: 38517066
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches.
Franke AJ; Skelton WP; Starr JS; Parekh H; Lee JJ; Overman MJ; Allegra C; George TJ
J Natl Cancer Inst; 2019 Nov; 111(11):1131-1141. PubMed ID: 31322663
[TBL] [Abstract][Full Text] [Related]
14. Combined Treatment with Immunotherapy-Based Strategies for MSS Metastatic Colorectal Cancer.
Baraibar I; Mirallas O; Saoudi N; Ros J; Salvà F; Tabernero J; Élez E
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944931
[TBL] [Abstract][Full Text] [Related]
15. The Expression Patterns of Immune Checkpoint Molecules in Colorectal Cancer: An Analysis Based on Microsatellite Status.
An S; Li W; Do H; Kwon HY; Kim B; Kim K; Kim Y; Cho MY
Biomedicines; 2024 Mar; 12(4):. PubMed ID: 38672108
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy and immunoevasion of colorectal cancer.
Al Zein M; Boukhdoud M; Shammaa H; Mouslem H; El Ayoubi LM; Iratni R; Issa K; Khachab M; Assi HI; Sahebkar A; Eid AH
Drug Discov Today; 2023 Sep; 28(9):103669. PubMed ID: 37328052
[TBL] [Abstract][Full Text] [Related]
17. Identifying and clinically validating biomarkers for immunotherapy in colorectal cancer.
Yeh YS; Tsai HL; Chen PJ; Chen YC; Su WC; Chang TK; Huang CW; Wang JY
Expert Rev Mol Diagn; 2023 Mar; 23(3):231-241. PubMed ID: 36908268
[TBL] [Abstract][Full Text] [Related]
18. PPARγ induces PD-L1 expression in MSS+ colorectal cancer cells.
Gutting T; Hauber V; Pahl J; Klapproth K; Wu W; Dobrota I; Herweck F; Reichling J; Helm L; Schroeder T; Li B; Weidner P; Zhan T; Eckardt M; Betge J; Belle S; Sticht C; Gaiser T; Boutros M; Ebert MPA; Cerwenka A; Burgermeister E
Oncoimmunology; 2021 May; 10(1):1906500. PubMed ID: 34026331
[TBL] [Abstract][Full Text] [Related]
19. A novel prognostic immunoscore based on The Cancer Genome Atlas to predict overall survival in colorectal cancer patients.
Tang Z; Wu Y; Sun D; Xue X; Qin L
Biosci Rep; 2021 Oct; 41(10):. PubMed ID: 34608935
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoints and cancer development: Therapeutic implications and future directions.
Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
